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Altered Regulation of Aquaporin Gene Expression in Allergen and IL-13-Induced Mouse Models of
Asthma
Carissa M. Krane, Bijia Deng, [...], and Melisa W.Y. Ho

Abstract
IL13 is known to affect many processes that contribute to an asthmatic phenotype, including inflammation, fibrosis, and mucus
production. Members of the aquaporin (AQP) family of transmembrane water channels are targets of regulation in models of lung injury
and inflammation. Therefore, we examined AQP mRNA and protein expression in allergen and IL13induced mouse models of asthma.
Lungs from ovalbumin sensitized and ovalbumin challenged (OVA/OVA) and IL13 treated mice showed airway thickening, increased
mucus production, and pulmonary eosinophilia. Pulmonary function tests showed a significant increase in methacholineinduced airway
hyperreactivity in OVA/OVA and IL13treated mice as compared with controls. Quantitative PCR analysis revealed differential
regulation of AQPs in these two models. AQP1 and AQP4 mRNA expression was downregulated in the OVA/OVA model, but not in the
IL13 model. AQP5 mRNA was reduced in both models, whereas AQP3 was upregulated only in the IL13 model. Western analysis
showed that diminished expression of an apically localized aquaporin, (AQP5), and concomitant upregulation of a basolateral aquaporin
(AQP3 or AQP4) are characteristic features of both inducible asthma models. These results demonstrate that aquaporins are common
targets of gene expression in both allergen and IL13 induced mouse models of asthma.
Keywords: IL13, aquaporin, AHR, asthma, lung, inflammation

1. Introduction
Allergic asthma is a complex disorder, which involves a significant contribution of environmental stimuli for the manifestation of
symptoms and degree of clinical severity. The salient features of allergic asthma involve inflammation, increased mucus production,
airway remodeling, temporary bronchoconstriction, and airway hyperresponsiveness to bronchoconstrictive agents [1]. Experimentally, the
model of intraperitoneal (i.p.) ovalbumin sensitization followed by intranasal (i.n.) or intratracheal (i.t.) ovalbumin challenge in mice
generates an allergeninduced asthmatic phenotype, which is characterized by IgE and T cell inflammatory responses, similar to what is
seen clinically in human patients [2]. Several previously published studies have established a role for IL13 in asthma [3,4,5].
Specifically, intranasal IL13 instillation produces airway hyperreactivity (AHR), mucus hypersecretion, subepithelial fibrosis, and
eosinophilia in mice [6,7]. Moreover, studies performed in a variety of different human subpopulations have identified genetic associations
between polymorphisms in a number of inflammatory response genes involving the IL4/IL13 pathway with atopic asthma [8,9,10,11]. A
number of experimental approaches have examined the neutralization of IL13 as a novel therapeutic strategy for allergic asthma [7,12].
While the exact mechanism is not clear, evidence suggests that alterations in ion and fluid homeostasis may be involved in IL13 induced
AHR [13, 14]. IL13 treatment is known to alter ion transport along the apical and basolateral membranes of bronchiolar epithelium,
thereby functionally converting this cell layer from an absorptive to secretory tissue [14,15]. Moreover, the mucus hypersecretion that
accompanies the IL13 mediated asthma phenotype is characterized by the upregulation of mucin genes and a calcium activated chloride
channel, further implicating changes in epithelial dependent fluid handling as a contributor to the asthmatic phenotype [13].
Aquaporins (AQPs) are a family of transmembrane water channels that mediate physiological and cellular responses to changes in fluid
volume and osmolarity. AQPs are required for normal secretory and absorptive functions of many tissues, including the eye, lung, salivary
gland, sweat glands, and kidney and provide essential systemic regulation of water homeostasis in whole organisms [16,17]. Four
aquaporins are expressed in the lung [18,19,20]. AQP1 is expressed in the apical and basolateral membranes of peribronchiolar and
alveolar endothelia, and in the visceral pleura. Studies of AQP1 null mice revealed a reduction of osmotic water permeability in capillary
endothelium [21] and AQP1 deficient or Colton null human patients exhibit decreased vascular permeability [22], implicating its
importance in water transport across the endothelium. AQP3 and AQP4 are expressed in the epithelium from the upper and lower
respiratory tract, respectively [19]. AQP3/AQP4 double knockout mice showed moderate reduction in osmotic water permeability in
upper airways but with little effect on salt content of airway surface liquid [20]. AQP5 is expressed at high level in type I pneumocytes in
the distal lung but moderately in epithelia from upper airway [23]. Functionally, AQP5 is important for regulating airspacecapillary
osmotic water permeability [24] and MUC5AC mucin secretion in airway submucosal glands [25,26]. A reduction in human AQP5
expression has been shown to be correlated with an increase in mucus production and compromised lung function in patients with chronic

obstructive pulmonary disease [27]. In addition, AQP5 function is critical in systemic pulmonary physiology where it facilitates the
maintenance of airway tone. Mice deficient in AQP5 are hyperresponsive to cholinergic stimulation, and exhibit a significant increase in
total lung resistance with an accompanying decrease in dynamic compliance [23]. The expression of AQPs is altered in various models of
lung infection [28], inflammation [29,30], acute and chronic injury [31,32], and fibrosis [33], indicating a role in these pathological
conditions. Therefore, in this study, we used two different mouse models of inducible asthma to investigate AQP mRNA and protein
expression in mouse lung. The data presented here show that AQP gene expression in mouse lung is differentially regulated in allergen
and IL13 induced mouse models of asthma, suggesting that alterations in fluid and ion handling in the lung may serve as important
mechanistic features of airway pathophysiology in these inducible asthma models.

2. Materials and Methods
2.1 Animal Models
Eightweekold female BALB/c mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and housed in a pathogenfree
environment. The Institutional Animal Care and Use Committee review board of Wyeth Pharmaceuticals approved all experiments
involving the use of live mice.
Antigen induced airway inflammation and hyperresponsiveness (AHR) 40 female BALB/c mice were randomly assigned to 2 groups. Mice were
immunized by i.p. injection with 20 μg of ovalbumin (OVA) emulsified in 2.25 mg alum (AlumImject; Pierce, Rockford, IL, USA) in a
total volume of 200 μl on days 0 and 14. To induce an allergic reaction within the lung, animals were challenged via the airways with
OVA (5% in PBS; OVA/OVA animals) or PBS (OVA/PBS animals) for 30 min on days 26, 27 and 28 by ultrasonic nebulization. AHR
measurement and sample collection were performed on day 30 (48 h after the last challenge).
IL-13 induced airway inflammation and hyperresponsiveness (AHR) BALB/c mice were challenged via the airways by i.n. administration of 5
μg of recombinant murine IL13 in a total volume of 50 μl on days 0, 1 and 2, whereas vehiclecontrol animals were given 50 μl of PBS
(n=40 per group) in a chronic exposure inflammatory model. Recombinant murine IL13 was expressed in E. coli, purified and refolded at
Wyeth Research. A three day course of administration of 5 μg of recombinant IL13 has been shown to produce consistent AHR and
induce lung remodeling [5]. Ten animals from each group were used for bronchoalveolar fluid (BALF) cell collection to evaluate lung
inflammation and the remaining 10 animals were used to study lung function on day 3 postIL13 instillation. Animals were sacrificed by
CO2 asphyxiation. The lungs were fixed or snap frozen for histochemical or expression analyses respectively. Measurements of AHR and
sample collection for quantitative realtime PCR, Western blots, and histochemical analyses were performed on day 3 (72 hrs). To
examine potential dose responsiveness, mice were challenged via the airways by i.n. administration of 0.5 or 10 μg of recombinant murine
IL13 in a total volume of 50 μl on days 0, 1 and 2. Lungs were harvested on day 3 (after 72 hours) and used for real time PCR and
Western blotting. Control groups included untreated and PBStreated mice.
To examine the effect of acute inflammation on aquaporin mRNA expression, mice were treated with a single dose of 10 μg of mIL13
by i.n. administration. Lung tissues were collected at 6, 24, 48 and 72 hr after mIL13 instillation, and used for quantitative realtime PCR
analysis.

2.2 Lung tissue preparation for histochemical staining
The lungs were excised, inflated, and fixed immediately with 700 μl with 4% paraformaldehyde in PBS administrated via the trachea.
Each sample was immersed in 4% paraformaldehyde in PBS for 24 hours to complete the fixation process. Fixed tissues were embedded
in paraffin wax within 48 hr for sectioning using an embedding unit (Leica model: EG1160). Fivemicron transverse serial sections were
cut for both histochemical and immunohistochemical staining. For histology, tissue samples were stained with hematoxylineosin (H&E),
Massons Trichrome (MT) or periodic acidSchiff (PAS) using standard methodologies. Images from samples were viewed and captured
by using Nikon microscope (Eclipse E800, Nikon Melville, NY, USA)) equipped with a CCD camera (Spot RT Slider, Diagnostic
Instrument Inc., Sterling Heights, MI, USA).

2.3 Measurement of inflammatory cell influx
The lungs were excised from mice and BALF was collected by flushing the lungs via the trachea 3X with 700 μl of PBS. Total BALF
cellular influx was quantified using a CellDyn coulter counter (CellDyn3500, Abbott Diagnostics, Abbott Park, IL, USA). Cell

differential was quantified using a Becton Dickenson Vantage SE Cell Sorter (Becton Dickenson, Franklin Lake, NJ, USA) configured
with a 488/10 filter plus a polarizing filter in front of the FL1 detector.

2.4 Measurement of lung resistance (RL) & dynamic compliance (cDyn)
Airway resistance (R) and dynamic compliance (cDyn) were evaluated as described previously [34]. Anesthetized, tracheostomized mice
were mechanically ventilated at a rate of 150 breaths/min and a tidal volume of 200 μl. Resistance computations were derived from the
tracheal pressure and airflow signals, using an algorithm of covariance. Aerosolization was performed by a nebulizer inline with the
inspiratory tubing from the ventilator. Aerosol was administered in narrow “puffs”, each puff a small part of each inspiration. A dose
consisted of twenty ventilator breaths. Increases in total resistance were analyzed over a threeminute period after the last puff.
Increasing methacholine concentrations within the nebulizer provided the successive steps of the dose response.

2.5 Quantitative real-time PCR (Taqman) analysis
Realtime PCR was used to evaluate lung aquaporin mRNA expression in the allergen OVA sensitization/OVA challenge model
(OVA/OVA; n=6), the OVA/PBS group (n=6), and naïve controls (n=5). Realtime PCR was also used to evaluate aquaporin expression
following a 3 day course (72 hr) of 5 μg i.n. administration of IL13, as well as potential dose responsiveness at 0.5 and 10 μg doses in a
chronic exposure inflammatory model (described above). The kinetics of AQP mRNA expression in mouse lung over a 72 hour time
course was examined using the acute inflammatory model described above in which mice were administered a single dose of 10 μg of IL
13. For all conditions, total RNA was extracted from frozen lung samples (n= 5 per group) using the RNeasy mini kit and manufacturer's
protocol (QIAGEN). Two Hundred and fifty ng total RNA in a 50 μl reaction mix was used for each reversetranscription/PCR with the
onestep protocol (Reverse Transcriptase qPCR Master Mix; EUROGENTEC) as follows: 48°C × 30 min (reverse transcription); 95°C ×
10 min (hot starting); 95°C × 15 sec/60°C×1 min for 40 cycles. Cycle number at Threshold (CT) was normalized to CT value for GAPDH
gene. All Taqman assays were performed on the ABI prism 7700 sequence detector (Applied Biosystems, Foster City, CA, USA). The
primers used for AQP1, AQP3, AQP4, AQP5, and glyceraldehyde 3phosphate dehydrogenase (GAPDH) (Genbank accession numbers
NM_007472, NM_016689, NM_009700, NM_009701, M32599, respectively) are shown in Table 1. Each result was fit to a standard curve
and cycle number at threshold values were normalized to GAPDH. The averages of the normalized AQP1, 3, 4, and 5 mRNA levels from
the OVA/PBS and OVA/OVA groups were expressed as percent change in expression vs. naïve controls. The averages of the normalized
AQP1, 3, 4, and 5 mRNA levels of the five animals from the IL13 treated were expressed as percent change in expression vs. controls.

Table 1
Oligonucleotide and probe sequences of AQPs and GAPDH for qPCR (Taqman Assay)

2.6 Western blot analysis
Rabbit polyclonal antibodies were generated against a synthetic peptide corresponding to the rat AQP1 (NH2
CEEYDLDADDINSRVEMKPKCOOH) and AQP5 (NH2CEPEEDWEDHREERKKTIELTAHCOOH) Cterminal residues and
conjugated to keyhole limpet hemocyanin (KLH; Zymed laboratories, San Francisco, CA, USA). The AQP1 and AQP5 antibodies were
affinity purified from serum with sulfolink coupling gel (Pierce, Rockford, IL, USA), conjugated with 2 mg of synthetic peptide. A pre
absorption control was performed with 1 mg of AQP1 or AQP5 peptide with 0.2 mg/ml of antibody preincubated overnight at 4°C. Pre
immune controls were conducted with 0.2 mg/ml of IgG purified preimmune serum from each rabbit. Rabbit polyclonal antibodies
directed to amino acids 180 of human AQP3 (sc20811) or amino acids 244323 of human AQP4 (sc20812) which cross react with
mouse AQP3 or AQP4 respectively were purchased from Santa Cruz Biotechnology. For the allergen exposure model, total membrane
protein fractions from the lungs of naïve (n=5), OVA/PBS (n=6), and OVA/OVA (n=6) mice were isolated. For the IL13 model, total
membrane protein fractions from the lungs of control (PBS) mice (n=10), and mIL13 treated mice (n=10) were isolated. For all
conditions, the total membrane preparations were quantified, size fractionated by SDSPAGE, and subjected Western analysis as
previously described [35]. Densitometry was used to quantify both Coomassie and India ink stained bands to confirm equivalent loading on
membranes as described [28]. AQP protein abundance was expressed as a percentage of control group expression.

2.7 Statistical Analysis
All data was reported as mean ± SE. The significance of the differences between the groups was determined by either a twotailed
student ttest with equal variance or a twoway ANOVA. A P value of < 0.05 was considered significant.

3. Results
3.1 mIL-13 intranasal instillation results in changes in lung architecture
To assess airway remodeling in the mIL13 induced asthma model, lung sections from mice treated with a threeday course of
intranasally administered IL13 (5 μg per dose) or PBS (controls), were examined for histological changes in airway architecture.
Hematoxylin and eosin (H&E) staining of lung sections from PBS control mice showed normal lung histology (Figure 1A) whereas lung
sections from the mIL13 treated mice confirmed the presence of airway thickening due to epithelial cell hyperplasia/metaplasia (
Figure 1C). Moreover, periodic acidSchiff (PAS) staining revealed hypersecretion of mucus in lungs of the mIL13 treated mice (
Figure 1D), as compared to the PBS controls (Figure 1B). Massons trichrome stain revealed no subepithelial fibrosis or collagen
deposition (data not shown). In addition, only the lung samples from OVA sensitized and OVA challenged (OVA/OVA) (
Figure 1G & Figure 1H) but not the OVA sensitized and PBS challenged (OVA/PBS) (Figure 1E & Figure 1F) mice showed thickening
of basement membrane and mucus hypersecretion, similar to previously published data from the classic antigendependent model of
asthma [36]. These data indicate that a threeday course of i.n. mIL13 administration caused alteration in lung structure by thickening of
epithelium and mucus hypersecretion.

Figure 1
IL13 and OVA induced lung remodeling

3.2 OVA sensitization/OVA challenge and mIL-13 instillation result in lung inflammation and reduced lung function
The degree of inflammation that occurred in the lungs of OVA/OVA and mIL13 treated mice was compared to their respective PBS
controls using bronchoalveolar lavage (BAL) total cell counts as well as differential eosinophil counts. Total BAL cell counts were
significantly higher in the OVA/OVA group as compared to the OVA/PBS control group, with 87×104 ± 7.1×104 cells from the OVA
challenged animals in comparison with 5.4×104 ± 0.9×104 cells from the PBS challenged animals (Figure 2A; p≤0.001; n=10). Similarly,
BAL cell counts were increased in mIL13 dosed mice with 30.5×104 ± 1.6×104 total cells collected in comparison with 8.5×104 ±
1.6×104 cells with PBS control (Figure 2C; p≤0.001; n=10). Additionally, eosinophil cell counts from the BAL were also significantly
higher in both models in comparison with the respective PBS controls (Figure 2B and 2D): 563×103 ± 51.6×103 cells with OVA
challenged animals in comparison with 3.5×103 ± 0.5×103 cells with PBS challenge (p≤0.001; n=10), and 51.1 × 103 ± 11.2 × 103 cells
with mIL13 treated animals in comparison with 1.7 × 103 ± 0.4 × 103 cells with PBS controls (p≤0.001; n=10). These results confirm that
both OVA/OVA and intranasal mIL13 administration generate pulmonary inflammation and eosinophilia, consistent with previously
reported results using similar models [4].

Figure 2
OVA and mIL13 enhance lung inflammation

To further characterize the antigen and IL13 induced asthma models, measures of total lung resistance (RL) and dynamic compliance
(cDyn) in response to methacholine challenge were used to assess AHR in treated mice as compared to the PBStreated group. Mice

subjected to OVA/OVA challenge as well as i.n. administration of mIL13 showed a significant increase in RL (OVA/OVA Figure 3A;
p≤0.05; n=7 ANOVA; mIL13 Figure 3B; p≤0.01; n=10 ANOVA) and decrease in cDyn (OVA/OVA Figure 3C; p≤0.05; n=7 ANOVA;
IL13 Figure 3D; p≤0.05; n=10 ANOVA) respectively, as compared to the PBS challenged mice, in response to increasing doses of
inhaled methacholine. These data demonstrate that AHR is induced in both OVA/OVA challenged and mIL13 instilled mice.

Figure 3
AHR in animals treated with OVA or mIL13

3.3 AQP mRNA and protein expression in OVA sensitized (OVA/PBS) and OVA challenged (OVA/OVA) mouse lung
Aquaporin mRNA expression was examined using quantitative real time PCR (Taqman) on lung samples taken from mice sensitized with
OVA (PBS), and those sensitized and subsequently challenged with OVA (OVA), and compared to expression in naïve control mice. The
levels of AQP1, 4, and 5 mRNA expression were similarly decreased by >75 % in the OVA challenged mice as compared to naïve
controls (Figure 4; p≤0.001, n=6 each). AQP3 mRNA expression was not altered in either the PBS or OVAtreated mice. Examination
of protein expression by immunoblotting revealed a concomitant decrease in AQP1 and AQP5 protein abundance in the OVA challenged
mice as compared to controls (Figure 5A and Figure 5B), consistent with the observed reduction in mRNA expression. AQP1 expression
significantly decreased by 27% as compared to control animals (p≤0.001), whereas AQP5 expression was reduced by ∼64% that of
controls (p≤0.0001). However, while no change in AQP3 mRNA expression was observed, AQP3 protein expression decreased by ∼92%
(p≤0.05). Furthermore, contrary to the reduction of AQP4 mRNA expression seen in the lungs from OVA challenged mice, AQP4 protein
abundance increased by 65% as compared to controls (p≤0.01).

Figure 4
mRNA expression of AQPs 1, 4, and 5 is significantly reduced in response to OVA challenge

Figure 5
Reduction in AQPs 1, 3, and 5 protein expression in OVAchallenged (OVA/OVA) mouse lungs

3.4 AQP mRNA and protein expression in mIL-13 induced models of asthma
In order to investigate potential kinetic regulation of AQP expression in the acute stages of IL13 induced asthma, real time quantitative
PCR (Taqman) was used to assess relative changes in AQP mRNA in mIL13 treated lungs following a single dose of 10 μg of IL13. A
significant increase (250%), in total lung AQP3 mRNA was detected within 24 hr (Figure 6A) as a consequence of IL13 administration
to the lung. In contrast, a significant decline in IL13 treated lung AQP5 mRNA expression level to ∼50% of the PBS treated control
lung, was detected within 24 hr (Figure 6A). A partial recovery of both AQP3 and AQP5 mRNA expression, comparable to that seen in
the PBS treated animals, was observed by 48 hours in the acute inflammation model. No significant changes in AQP1 and AQP4 mRNA
expression were observed at 24 hr. AQP3 and AQP5 mRNA expression was also examined after a 3 day course of IL13 administration
(5 μg) in a chronic exposure model of IL13 induced asthma. A ∼60% decrease in AQP5 expression was observed 24 hours after the last
dose of IL13 (p<0.01; Figure 6B), whereas as AQP3 expression was not significantly different than PBS controls in the chronic exposure
model (Figure 6B). Additional experiments were conducted to examine potential doseresponsiveness of IL13 induced changes in AQP3

and AQP5 mRNA expression. No significant changes in AQP mRNA expression were observed between 0.5 μg, 5 μg or 10 μg doses of
IL13 (data not shown).

Figure 6
AQP3 mRNA expression level is increased and AQP5 mRNA expression is decreased in response to mIL13 administration

To assess if the changes in AQP3 and AQP5 mRNA expression are accompanied by changes in protein levels, AQP protein expression in
mIL13 treated mice (3 doses of 5 μg IL13) relative to PBS controls was examined by immunoblotting. At 72 hours, AQP3 protein was
increased by ∼112% (p<0.05) as compared to PBS controls (Figure 7A and 7B). Consistent with IL13 effects on AQP5 gene expression,
densitometric analysis of Western blots of total membrane proteins showed an ∼60% reduction in AQP5 protein expression in lungs of
mIL13 treated mouse lung, as compared to PBS controls (p<0.05; Figure 7A and 7B). IL13 treatment did not result in statistically
significant changes in either AQP1 or AQP4 protein expression. Varying the dose of IL13 (0.5 and 10 μg; data not shown) did not result
in differences in the level of AQP expression as compared to that which was observed with the 5 μg IL13.

Figure 7
Increase in AQP3 and decline of AQP5 protein expression in lungs from mIL13 treated mice

4. Discussion
In characterizing the potential implications of therapeutic IL13 blockade, it is important to elucidate the molecular mechanisms of IL13
induced asthma pathogenesis and regulatory effects on AQPs. The data presented here identify AQPs as potential downstream targets of
the inflammatory response to allergen and IL13 induced asthma. Mice subjected to OVA sensitization/OVA challenge, or mIL13
instillation, showed characteristic allergic asthma pathology: epithelial thickening, mucus hypersecretion and pulmonary eosinophilia
accompanied by a significant increase in methacholineinduced AHR, as compared with control animals. Examination of AQP expression
in these models revealed modelspecific patterns of gene regulation. In the allergen model, OVA sensitization/OVA challenge resulted in
a significant reduction in AQP1 and AQP5 lung mRNA and protein expression. While AQP3 mRNA level remained unchanged, AQP3
protein expression was diminished. To the contrary, AQP4 mRNA expression was significantly reduced, while AQP4 protein expression
was in greater abundance as compared to the controls. The mechanisms regulating the observed gene expression are likely to be complex.
It is likely that AQP3 mRNA expression levels have returned to normal levels, but were subject to early transcriptional regulation. This
interpretation of the allergen model data is supported by the observed acute changes that occur in AQP3 mRNA expression which shows a
trend as early as 6 hours, then peak at 24 hours, and subsequently return to normal levels by 48 hours in the IL13 model. Thus it is
possible that the disparity between AQP3 mRNA and protein levels in the OVA model is due to the rate of AQP3 protein translation
and/or mRNA or protein turnover which may be differently regulated in part through allergen and/or cytokine (IL13) mediated pathways.
Similarly, it is also important to note that whereas AQP4 mRNA expression was downregulated in the OVA model, AQP4 protein
expression was upregulated in the OVA model. These observations may also involve a potential complexity of posttranscriptional and
posttranslational regulation which remains to be discerned.
In the IL13 instillation models, the regulation of mRNA expression of these four AQPs was more complex. AQP3 mRNA was acutely
upregulated by IL13 in the single dosing regimen (10μg/kg), but was not affected in the chronic dosing (3× 5μg/kg) regimen, suggesting
that AQP3 mRNA is subject to acute regulatory signals. AQP5 mRNA was consistently downregulated in both IL13 dosing regimens. A
slightly different pattern of regulation was observed for AQP1, AQP3, and AQP4 in the chronic mIL13 model, in comparison with the
OVA/OVA model. In the mIL13 chronic model, there was no change in either AQP1 or AQP4 protein expression, whereas AQP3

protein expression was increased approximately two fold as compared to control. Thus, it appears that AQP3 upregulation is an early
event, which is followed by AQP3 protein upregulation as AQP3 mRNA abundance returns to steady state levels. Finally, as observed in
the OVA model, AQP5 protein expression was also significantly reduced in the mIL13 instilled mouse lungs.
Collectively, these data show that diminished expression of an apically localized aquaporin, (AQP5), and concomitant upregulation of a
basolateral aquaporin (AQP3 or AQP4) are characteristic features of both inducible asthma models. Significant reductions in AQP5
mRNA and protein levels were observed in the allergen as well as the acute and chronic mIL13 models. Thus, the downregulation of
AQP5 may be a regulatory target for allergeninducible asthma, and in IL13 mediated AHR. AQP5 is the only known AQP expressed on
the apical surface of airway and submucosal gland epithelium [23,24]. The in vivo AQP5 expression regulation reported here, confirms
the in vitro observations reported recently where IL13 treatment was shown to abolish AQP5 expression in primary cultures of human
airway epithelial cells [15]. Therefore, the consistent downregulation of AQP5 (both mRNA and protein) in both models implies an
important feedback mechanism for the diminished capacity of apical membrane water permeability in these models [15].
Coinciding with the down regulation of AQP5, an increase in AQP4 protein expression occurred in the OVA model, whereas AQP3
protein expression was increased upon IL13 instillation. Both AQP3 and AQP4 are expressed on the basolateral membrane of epithelium
from the upper and lower respiratory tract, respectively [19]. Therefore, the upregulation of an AQP on the basolateral membrane
appears to be a consistent event in both models, and might be responsible for increase fluid flux across the epithelium in asthma.
Overall, the data presented here implicate alterations in water channel expression levels with abnormal airway responses in two distinct
mouse models of inducible asthma, the OVA sensitized/OVA lung challenge model and a second model in which intranasal instillation of
IL13 leads to asthmatic changes. Both the allergen and cytokine induced asthma models lead to temporary and reversible
bronchoconstriction, long term airway remodeling, and airway inflammation, which involve complex gene regulation [37]. These changes
are related to alterations in the physiological mechanics of the lung. However, there are some important mechanistic differences between
the models which generate different physiological responses. In the OVA model, several proinflammatory cytokines and chemokines are
induced in the lung, including IL13, IL5, MCP1, and TARC [38], resulting in an escalation of the immune response. IL13 is a critical
mediator of the respiratory changes in the OVA allergen sensitization/OVA challenge model [7]. In comparison, the mIL13 instillation
model results in an acute and localized cellular response driven by cytokine instillation [4]. Although many of the lung function changes
induced by OVA immunization and challenge are IL13driven [4], the observed differences in AQP3 protein levels could simply
explained by the difference in the time point chosen for analysis (24 hrs after last dose of IL13 vs 48 hrs after the last OVA challenge).
In the rat model of edema, animals treated with thiourea show an increase in AQP3 protein within 410 hours [32], supporting that AQP3
protein are subjected to acute regulation. The rapid regulation of AQP3 might signify an important physiological feedback mechanism to
acutely adjust fluid balance across epithelium. Alternatively, the difference in immune responses in these two models might explain the
differential regulation of AQP3 by multiple cytokines. Downregulation of AQP3 expression has been linked to mucus production in
endobronchial biopsies of patients with bronchiectasis [39]. Similarly, we observed mucus production in both the OVA and IL13
instillation models. Our observation of reduced AQP3 protein in the lungs of OVAtreated animals may reflects a change in cellular
phenotype of epithelial cells from absorptive to secretory under prolong inflammatory condition. Future studies will explore the
relationships of AQP3 expression and mucus production in the OVA model.
Regulatory alterations in the expression of aquaporin (AQP) mRNA and protein have been further documented in various models of lung
injury and disease. A reduction in AQP1 protein expression was observed in response to lipopolysaccharideinduced acute lung injury
[31]. In a thiourea induced pulmonary edema model, AQP3 mRNA and protein levels were increased within 4 hours posttreatment,
whereas AQP1, AQP4 and AQP5 mRNA levels were significantly reduced [32]. Moreover, AQP5 mRNA and protein expression were
significantly reduced in association with pulmonary inflammation and edema resulting from adenoviral infection [28], bleomycininduced
lung fibrosis [33], and hyperoxiainduced lung injury [40]. Similarly, direct intratracheal instillation of proinflammatory agent
phospholipase A2 caused a reduction in AQP5 expression in rat [29]. Furthermore, AQP5 mRNA and protein expression in a murine lung
epithelial cell line (MLE12) was also inhibited by the proinflammatory cytokine TNFα through a nuclearfactor (NF) κBdependent
pathway [30]. Taken together, these published studies indicate that AQPs serve as common regulatory targets for altered gene expression
during lung infection, inflammation, acute and chronic injury, airway remodeling and under pathophysiological conditions of altered lung
function. The data presented here suggest that alterations of AQP3 and AQP5 gene expression may be a relatively early event in the
lung's response to mIL13 induced airway pathology. Though the physiological implications of this altered regulation are not currently
defined, the identification of AQPs among the genes that are subject to differential gene expression in response to allergen and IL13
induced asthma, indicates that AQPs may be an important new functional category of genes involved in this response. These data also

suggest that further evaluation of AQP gene expression, posttranslational regulation and function in other experimental models of asthma
is warranted.
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